Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Identifying Immunological Basis for Bladder Cancer Sex Bias

Funder: Canadian Institutes of Health Research

Funding period
CAD 35 K
USD 26 K
Funding amount
Abstract
Bladder cancer incidence shows an enigmatic male bias, as it is the 4th most common cancer in men but only the 12th most common cancer in women in Canada. The bias cannot be fully accounted for by lifestyle factors such as smoking, suggesting that it is likely a consequence of more fundamental biological differences between two sexes. To this end, we analyzed human primary bladder cancers and discovered that immune pathways are more enriched in women than in men, which hinted that sex bias may be driven by sex-specific differences in immune function. To address this possibility, we utilized the preclinical murine bladder cancer models that recapitulate the male bias seen in human bladder cancer. Remarkably, we observed that hormonally mediated differences in T cell immunity are responsible for sexual dimorphism in tumor growth. Our Research Proposal seeks to determine exact mechanisms by which sex hormones regulate T cell immunity. Male-based studies predominate in immunology research despite clear evidence that sex discrepancy exists in the outcome from many infectious and autoimmune diseases, vaccines and malignancies. Erroneous assumption that such results can be generalized to both sexes not only damages the scientific rigor and reproducibility but is also a major barrier to the long-term goal of personalizing treatments for immune-related diseases. Specific study design in our Proposal, explicitly aiming to highlight the immune mechanisms underlying unique protection against bladder cancer in females, presents an innovative approach to identify novel therapeutic targets. Also, completion of proposed research will establish an important insight that anti-tumor immunity may be largely different between men and women, thereby emphasizing sex as a critical biological variable to consider in designing future pre-clinical/clinical immunotherapy studies.
Similar projects All >
Sorted by: Start Date
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, JOHN ROGERS, ARUN SHARMA

USD 709,004
2019 - 2023
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer

National Cancer Institute to LUBOMIR M HADJIYSKI, AJJAI SHIVARAM ALVA

USD 653,319
2019 - 2024
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Marianna Kruithof-de Julio, Vera Genitsch, Franziska Singer, Kiu Yan Charlotte Ng, Eugenio Zoni

USD 702,564
2019 - 2023

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Immunization

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science